DUBLIN--(BUSINESS WIRE)--The "Hypertrophic Cardiomyopathy - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Hypertrophic Cardiomyopathy - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Hypertrophic Cardiomyopathy (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypertrophic Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertrophic Cardiomyopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes; the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Hypertrophic Cardiomyopathy (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Report Coverage
- Hypertrophic Cardiomyopathy - Overview
- Hypertrophic Cardiomyopathy - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Hypertrophic Cardiomyopathy - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hypertrophic Cardiomyopathy - Companies Involved in Therapeutics Development
- C&C BioPharma LLC
- Lead Discovery Center GmbH
- MyoKardia Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/jjdcxs/hypertrophic?w=4